AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · New Hampshire

HB216

Exempting dimethyltryptamine from the controlled drug act.

Status

Did not pass; died when the session ended

2023 Session

IntroducedJan 3, 2023 (done)
PassedDid not happen (skipped)
SignedDid not happen (skipped)
Law in effectDid not happen (skipped)

Sponsor: Matthew Santonastaso (Republican)
Type: Scheduling/Trigger Law
Substances: DMT

Official text

Summary (from PoliPsy)

Exempting dimethyltryptamine from the controlled drug act.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: gc.nh.gov

Legislative history

March 9, 2023
Inexpedient to Legislate: Motion Adopted DV 274-97 03/09/2023 House Journal 8 P. 27
February 27, 2023
Committee Report
February 27, 2023
In Committee
January 3, 2023
Referred
January 3, 2023
Introduced

Loading bill…